Codis Completes Acquisition of Catalent’s Nottingham, UK Facility

Editor’s take: Adding formulation and clinical supply expertise, the Nottingham site complements Codis’ commercial‑scale PSD‑4 investment in Haverhill, UK, creating a comprehensive spray dry pathway from development to commercial intermediates and final dose forms.

Codis, a global CDMO specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering services, has completed its acquisition of Catalent’s Nottingham, UK facility. 

The acquisition expands Codis’ spray dry offering, combining development‑scale spray drying, oral solid dose (OSD) formulation, analytical services, clinical supply, and small‑scale commercial manufacturing in Nottingham with the company’s commercial spray drying operations in Haverhill. 

“This is an exciting milestone for Codis,” said Nicolas Fortin, CEO of Codis. “We are delighted to welcome the Nottingham team into the Codis family. Their scientific strength, development experience, and long track record of delivering high‑quality spray‑dried and oral solid dose solutions make them an exceptional addition to our organization. Together, Nottingham and Haverhill create a uniquely integrated pathway that allows customers to move from development to commercial manufacturing with greater speed, confidence, and continuity.”   

Codis’ large‑scale commercial spray drying facility in Haverhill is undergoing significant expansion with a new GEA Pharma‑SD PSD‑4 commercial spray dryer scheduled for validation in 2027. The combined capabilities will enhance Codis’ portfolio of bioavailability enhancement services for early development through clinical supply and commercial intermediates to final oral dose forms.